+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 44 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating etavopivat, a new oral medicine being developed for blood disorders such as sickle cell disease and thalassaemia. These inherited conditions affect hemoglobin, the protein responsible for carrying oxygen in the body. This long-term study aims to assess the safety and effectiveness of etavopivat treatment over a period of up to 264 weeks, or until the drug is approved in the participants country. Participants will receive one of several oral doses of etavopivat, with dosing adjusted by age those 12 years and older will receive Etavopivat A or C, while children younger than 12 years will receive Etavopivat B. The study involves multiple groups including adults, adolescents, and children with different types of sickle cell disease or thalassaemia. All participants have completed a prior etavopivat treatment study and are continuing treatment in this rollover study. During the study, participants will be regularly monitored for treatment-related side effects and clinical benefits. Researchers will track adverse events, blood crisis rates, hemoglobin levels, hospitalizations, and blood transfusion needs. The study includes long-term safety and efficacy assessments conducted over several years, with monitoring continuing until study completion or drug approval. Participants health and treatment responses will be carefully followed throughout this extended period.

Age: 2Years +All GendersPhase 3
107 locations
G

Actively Recruiting

Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.

Age: 12Years +All GendersPhase 3
175 locations
E

Actively Recruiting

Researchers are evaluating the pharmacokinetics and safety of etavopivat in children with sickle cell disease SCD. The study involves pediatric participants ranging in age from 6 months to less than 18 years and is designed as a phase 2, open-label, single-group study. Participants will be enrolled in age-based cohorts starting with the oldest group, with younger groups added sequentially after reviewing safety and pharmacokinetic data from prior cohorts. Participants will receive oral etavopivat once daily as either tablets or granules. The treatment includes a primary period lasting 24 weeks, followed by a 72-week extension period to further assess long-term safety and pharmacokinetics. The total study duration for each participant is approximately 96 weeks. Four age cohorts are studied 12 to less than 18 years, 6 to less than 12 years, 2 to less than 6 years, and 6 months to less than 2 years. Throughout the study, participants will be closely monitored with blood tests measuring etavopivat levels and hemoglobin changes, assessments of vaso-occlusive crisis frequency, and fatigue scales. Safety is evaluated by tracking adverse events, dose changes, and treatment interruptions. Transcranial Doppler ultrasound is used to assess cerebral blood flow at scheduled visits. The study includes frequent evaluations during both treatment periods to understand the drugs effects and safety in this young population.

Age: 6Months - 18YearsAll GendersPhase 2
18 locations
C

Actively Recruiting

Healthy Volunteer

This research aims to compare two behavior guidance methods to reduce anxiety in children during local anesthesia injections in dental care. It focuses on children aged 5 to 7 years who need local anesthesia for routine dental treatment. The study evaluates the traditional Tell-Show-Do technique against an artificial intelligence-driven avatar video called the Mini Dentist to see which better helps reduce fear and improve cooperation. Children will be randomly assigned to one of two groups. One group will watch the AI avatar video that explains and demonstrates the injection in a child-friendly way before the procedure. The other group will receive the conventional Tell-Show-Do method, where the dentist verbally explains and shows the procedure before performing it. All injections follow the same standardized protocol and are done by the same pediatric dentist. Participants will have their anxiety measured by monitoring heart rate at five specific times during the injection visit. Pain and behavior will also be assessed using the FLACC behavioral scale and the Wong-Baker FACES pain rating scale. Video recordings of behavior during the injection will be reviewed by trained evaluators. The study is voluntary and approved by an ethics committee, aiming to see if the AI-based method improves anxiety control and cooperation during dental injections.

Age: 5Years - 7YearsAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are gathering real-world data on the outcomes of patients with perimembranous ventricular septal defects PmVSD, a heart condition, who have undergone transcatheter closure using various device occluders. This international, multicenter, non-interventional, observational study aims to evaluate how well these devices work and their safety when used in both children and adults. The study focuses on patients treated with devices either specifically designed for PmVSD closure or used off-label. Participants in this study have had their PmVSD closed using commercially available occluder devices through a transcatheter procedure. The devices are placed without open-heart surgery to close the defect. The study observes patients who have already undergone this procedure and collects follow-up data according to each hospitals usual practice. The study does not intervene but monitors how these devices perform over time. Participants will be followed for up to 60 months after their procedure to assess clinical success, technical success, closure success, and any device-related complications. Researchers will also evaluate functional outcomes and quality of life for up to 48 months post-procedure. Data collection includes clinical events from the implant attempt through the follow-up period, and safety is monitored by tracking adverse events. The total duration of participation depends on the timing of the procedure and follow-up visits according to local protocols.

Age: 1Month +All Genders
25 locations
L

Actively Recruiting

This research evaluates the long-term safety of asciminib treatment in patients with Philadelphia chromosome-positive chronic myelogenous leukemia CML or acute lymphoblastic leukemia ALL who have completed a prior Novartis-sponsored asciminib study. It is designed to provide continued treatment for participants who, as judged by their investigator, would benefit from ongoing therapy but cannot access it outside the trial. This open-label, multi-center, global roll-over study focuses on assessing safety over an extended period. Participants receive asciminib or other related drugs such as imatinib, nilotinib, bosutinib, or dasatinib, either alone or in combination, based on their previous study treatments. Dosing varies with the specific drug for example, asciminib is taken orally once or twice daily, sometimes in fasting state, and pediatric participants receive a body weight-adjusted dose of asciminib granules. The study includes groups continuing their previous treatment, some switching from bosutinib or dasatinib to asciminib, and combinations with other tyrosine kinase inhibitors. Participants are monitored for adverse events and serious adverse events over eight years as the primary safety outcome. Secondary outcomes include clinical benefit assessments by investigators. During the study, participants undergo scheduled visits, treatment adherence tracking, and safety monitoring. The study spans from August 2022 to August 2030, allowing long-term observation of treatment effects and safety in this patient population.

Age: 7Years - 100YearsAll GendersPhase 4
85 locations
S

Actively Recruiting

This research focuses on understanding impedance across different tissue types during ultrasound-guided nerve blocks, including the axillary, interscalene, and popliteal sciatic nerve blocks. The study aims to evaluate how tissue resistance to electrical current affects nerve stimulation and visualization, which could help improve needle placement precision and reduce complications like intraneural or intravascular injections. This observational study is sponsored by Lebanese American University and will run over two years. Participants will undergo nerve blocks guided by ultrasound to measure impedance in various tissues such as skin, fat, fascia, muscle, and near nerves. The study is exploratory and does not involve any additional interventions beyond standard nerve block procedures. The focus is on collecting data on tissue impedance during these procedures to better understand its impact on nerve block accuracy. During the study, participants will be monitored while receiving these nerve blocks, with impedance measurements taken throughout the procedure. Researchers will assess the impedance levels across different tissue types during axillary, popliteal, and interscalene nerve blocks. The primary outcome is to understand impedance variation across tissues over two years. Participants safety will be monitored, and the total duration of involvement will align with the time needed for these measurements within the study period.

Age: 18Years - 90YearsAll Genders
1 location
I

Actively Recruiting

Benign prostatic hyperplasia BPH is a common condition affecting men, especially with increasing age, and is one of the most performed surgical procedures in urology. This study establishes an ongoing international registry under uCARE to collect and analyze demographic data and clinical outcomes for men undergoing medical or surgical treatments for BPH. The registry aims to provide real-world data on treatment patterns and outcomes worldwide, helping to identify practice trends and preferences. Participants included are men aged 18 years and older diagnosed with BPH and lower urinary tract symptoms LUTS who have been prescribed either medications or surgical interventions for BPH. The registry records baseline demographic and clinical data, peri-operative details, and follow-up information using validated tools such as the International Prostate Symptom Score IPSS, Sexual Health Inventory for Men SHIM, and Male Sexual Health Questionnaire for Ejaculatory Dysfunction MSHQ-EjD, as well as clinical measures like quality of life, maximum flow rate, post-void residual, prostate-specific antigen, and testosterone levels. Complications including bleeding, urinary tract infections, incontinence, and sexual dysfunction are also tracked. Participants medical records are securely entered into the registry with data validation and periodic audits to ensure accuracy. Data collection continues for three years with no fixed endpoint for follow-up, allowing for ongoing research and publication of findings. Access to registry data is protected and restricted to site-specific users, ensuring patient privacy and data security. The registry aims to support future studies and improve understanding of BPH treatment outcomes globally.

Age: 18Years +MALE
30 locations
S

Actively Recruiting

Healthy Volunteer

This research aims to investigate how specific genetic variations, particularly the A118G single-nucleotide polymorphism SNP in the mu-opioid receptor 1 OPRM1 gene and several SNPs in the Catechol-O-methyltransferase COMT gene, may influence postoperative pain and other recovery-related outcomes in children aged 8 to 18 undergoing various surgeries including orthopedic, abdominal, thoracic, and plastic procedures. The study focuses on understanding differences in pain sensitivity and opioid response among children due to these genetic factors. This is a prospective observational study involving about 200 children who will be monitored for their postoperative pain scores and other recovery aspects without altering their usual care. Researchers will assess pain levels, sedation, opioid use during and after surgery, the duration of stay in the post-anesthesia care unit PACU, and occurrences of respiratory depression or nausea and vomiting. Genetic testing will be conducted, but the study does not involve any experimental treatments. Participants will be evaluated during surgery and until discharge from the PACU, approximately 3 hours postoperatively. Data collected include pain scores, sedation levels, opioid requirements, and recovery duration, along with monitoring for side effects like respiratory depression and nausea. The study will use statistical analyses to explore how genetic differences relate to these outcomes, with the goal of improving personalized pain management for children undergoing surgery.

Age: 8Years - 18YearsAll Genders
1 location
C

Actively Recruiting

Researchers are evaluating sedation protocols for adults undergoing cataract surgery to find the best approach for patient comfort and safety. This study compares the effects of three sedation methods dexmedetomidine combined with fentanyl, propofol combined with fentanyl, and a combination of dexmedetomidine, propofol, and fentanyl. The goal is to understand how these protocols impact sedation levels, heart rate, blood pressure, respiratory events, surgeon satisfaction, and side effects like bradycardia, hypotension, and nausea. Participants will be randomly assigned to one of three groups receiving different sedation treatments. The dexmedetomidine groups receive a loading dose followed by maintenance infusion, propofol is given via target-controlled infusion to reach a specific sedation level, and all groups receive a single bolus of fentanyl. Three anesthesiologists will administer the protocols during elective cataract surgery on one or both eyes, with monitoring throughout the procedure and recovery. During the study, trained anesthesiologists and nurse anesthetists will assess sedation using the Ramsay sedation scale during surgery and in recovery. Participants will be closely monitored for vital signs and adverse effects. Surgeons will share their satisfaction with the sedation. The main outcomes measured are sedation levels during surgery and recovery, tracked over approximately one year. Safety and comfort will be carefully observed throughout the study period.

Age: 18Years +All GendersPhase Not Applicable
1 location

1-10 of 44

1